Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 22 Breast 18 Tumor-Agnostic 3 Head & Neck 3 Other solid neoplasm 2 NET 1 Gynecologic 1 Endocrine 1 CNS 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 6 Specimen Handling 4 Magnetic Resonance Spectroscopy 4 cabozantinib 3 pembrolizumab 2 olaparib 2 fludarabine 2 X-Rays 2 Phantoms, Imaging 2 Cyclophosphamide 2 tivozanib 1 repotrectinib 1 pazopanib 1 fludarabine phosphate 1 entrectinib 1 belinostat 1 atezolizumab 1 aldesleukin 1 Yttrium-90 1 Watchful Waiting 1 Tomography, X-Ray Computed 1 Tomography, Emission-Computed, Single-Photon 1 Temozolomide 1 Sunitinib 1 Single Photon Emission Computed Tomography Computed Tomography 1 Salts 1 Positron Emission Tomography Computed Tomography 1 PT-100 dipeptide 1 Octreotide 1 Nivolumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Capecitabine × NET × 30 days × Clear all

NCT04339036 2026-06-04

CapTemY90

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡